Richmond, CA. / Frankfurt - September 16, 2008 – Nanostart holding Lumiphore, Inc announced that they have signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City, California.
Under the agreement, Biophor Diagnostics holds the exclusive rights to apply Lumi4 TM technology to current and future diagnostic tests for drugs of abuse. Lumi4TM fluorescent metal-reporter compounds bring excellent fade-resistant photophysical properties, increased sensitivity, stability, and robustness to assays in the drugs of abuse testing market.
Drugs of abuse testing are a rapidly growing -billion market segment of the human in vitro diagnostics market. This is Lumiphore's third partnership with the other two being CisBio International (www.htrf.com/company/partners/) for the drug discovery research market and Echelon Biosciences Inc. (www.echelon-inc.com) for novel cancer assays involving phospholipid signalling and lipid-protein interactions. In August 2007, Nanostart has become lead-investor at Lumiphore, increasing its share by more than 20%. Nanostart will further expand its business on the U.S. market. Already today, the company invests at eye level with important U.S. Venture Capital companies.
About Lumiphore:
Based in Richmond, California, Lumiphore is a biotechnology company developing proprietary fluorescent-metal lanthanide technology for use in high-value applications and commercializing the technology by entering into market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. Metal lanthanide reporters provide increased sensitivity for fluorescent reagents in biology, since they make possible time-resolved detection vastly improving assay signals over background noise. For more information about Lumiphore, log onto www.lumiphore.com Lumi4TM is a trademark of Lumiphore, Inc.
About Nanostart:
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
